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Abstract
C-type lectin receptors (CLRs) offer unique advantages for tailoring immune responses. Engagement of CLRs regulates antigen
presenting cell (APC) activation and promotes delivery of antigens to specific intracellular compartments inside APCs for efficient processing and presentation. In these studies, we have designed an approach for targeted antigen delivery by decorating the
surface of polyanhydride nanoparticles with specific carbohydrates to provide pathogen-like properties. Two conserved carbohydrate structures often found on the surface of respiratory pathogens, galactose and di-mannose, were used to functionalize the surface of polyanhydride nanoparticles and target CLRs on alveolar macrophages (AMφ), a principle respiratory tract APC. Co-culture of functionalized nanoparticles with AMφ significantly increased cell surface expression of MHC I and II, CD86, CD40 and
the CLR CIRE over non-functionalized nanoparticles. Di-mannose and galactose functionalization also enhanced the expression
of the macrophage mannose receptor (MMR) and the macrophage galactose lectin, respectively. This enhanced AMφ activation
phenotype was found to be dependent upon nanoparticle internalization. Functionalization also promoted increased AMφ production of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. Additional studies demonstrated the requirement of the MMR for
the enhanced cellular uptake and activation provided by the di-mannose functionalized nanoparticles. Together, these data indicate
that targeted engagement of MMR and other CLRs is a viable strategy for enhancing the intrinsic adjuvant properties of nanovaccine adjuvants and promoting robust pulmonary immunity.
Keywords: Polyanhydrides, Nanoparticles, Carbohydrates, Alveolar macrophages

1. Introduction
Acute respiratory infections cause 4.25 million deaths worldwide every year.1 A critical need exists for the development of efficacious
intranasal vaccines against respiratory pathogens capable of inducing robust and protective mucosal immunity. In this regard, there is
growing interest in the development of vaccines that can be easily
administered to the site of infection in order to elicit both local and
systemic immune responses.2–5
The study of alveolar macrophages (AMφ), a type of antigen
presenting cell (APC) in the respiratory tract, is central to the development of intranasal vaccines. AMφ constitute more than 80%
of the total cells obtained by bronchoalveolar lavage of a healthy
individual and they constitutively migrate from the lung to the
draining lymph nodes (DLN).6–8 Indeed, AMφ containing bacteria appear in the pulmonary DLN prior to the onset of pathogen-

induced DC migration, thereby making them integral to the establishment of protective pulmonary immune responses.6 AMφ are
equipped to detect pathogens with the aid of pattern recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMPs).9 One family of PRRs found on AMφ, known as Ctype lectin receptors (CLRs), recognize conserved carbohydrate
structures, including mannose and galactose, found on the surface
of many respiratory pathogens, such as Yersinia pestis, Mycobacterium tuberculosis, Streptococcus pneumoniae and influenza viruses. 10–14 CLRs also function as phagocytic receptors and include
members of the mannose receptor family and DC-SIGN (dendritic
cell-specific intercellular adhesion molecule-3-grabbing non-integrin).15. Depending on the specific CLR, ligand binding initiates
downstream signaling cascades that promote immune cell migration to the DLN as well as antigen processing and presentation via
MHC I and/or MHC II to prime naïve T cells.16–20
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Several research groups have explored CLR targeting as a vaccine
design strategy to promote efficient delivery of cargo to intracellular
compartments responsible for antigen processing and presentation.21–29
Many studies have demonstrated the effectiveness of using antibodies22 or mannoproteins from pathogens26 to target CLRs and activate
APCs. However, only a limited number report the use of carbohydrate-functionalized vaccine carriers as part of an improved adjuvant
for intranasal vaccines.21, 24 Work published by Jiang et al. indicated
that alveolar macrophages could recognize mannosylated chitosan microparticles when delivered intranasally.24 Unfortunately, mechanistic studies demonstrating the engagement of the mannose receptor on
AMφ by these particles were not performed. Here, we describe functionalization of polyanhydride nanoparticles with two conserved carbohydrate structures commonly found on the surface of respiratory
pathogens, di-mannose and galactose. We also investigate the mechanisms by which these functionalized polyanhydride nanoparticles are
internalized by and influence the activation of AMφ.
2. Materials and methods
2.1. Materials
The chemicals needed for monomer synthesis, polymerization and nanoparticle fabrication included 1,6-dibromohexane, triethylene glycol, 4-p-hydroxybenzoic acid, and 1-methyl-2-pyrrolidinone; these were purchased from
Sigma–Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile was obtained from
Apollo Scientific (Cheshire, UK); toluene, sulfuric acid, acetonitrile, dimethyl
formamide, acetic anhydride, methylene chloride, pentane, and potassium carbonate were obtained from Fisher Scientific (Fairlawn, NJ); p-carboxy benzoic acid (99+%), and 1-methyl-2-pyrrolidinone, anhydrous (99+%) were
purchased from Aldrich (Milwaukee, WI). For 1H NMR characterization, deuterated chemicals, including chloroform and dimethyl sulfoxide, were purchased from Cambridge Isotope Laboratories (Andover, MA).
2.2. Monomer and polymer synthesis
The
1,6-bis(p-carboxyphenoxy)hexane
(CPH)
and
1,8-bis(pcarboxyphenoxy)-3,6-dioxaoctane (CPTEG) monomers were synthesized as
30,
31
previously described.
Random copolymers with a 50:50 ratio of CPH and
CPTEG were synthesized by melt polycondensation using an automated robotic deposition apparatus operated with LabVIEW® (National Instruments) as
previously described.31–35 The chemical structure of the polymers was characterized via 1H NMR with a Varian VXR 300 MHz spectrometer (Varian Inc.,
Palo Alto, CA). Deuterated chloroform was used to dissolve the polymer and
spectra were calibrated with respect to the chloroform peak (δ = 7.26 ppm).
The polymer molecular mass was determined using gel permeation chromatography (GPC). Samples were dissolved in HPLC-grade chloroform and
separated on a Waters GPC chromatograph (Milford, MA) containing PL gel
columns (Polymer Laboratories, Amherst, MA) comparing elution times to
monodisperse polystyrene standards (Fluka, Milwaukee, WI).
2.3. High throughput synthesis of carbohydrates
A robotic set up was used for the iterative synthesis of linear α-1,2-linked
di-mannose with a fluorous allyl group using fluorous solid phase extraction
(FSPE) serving as a model to obtain the di-mannoside.21, 36–38 Carboxymethyl
– di-mannose synthesis was performed by ozonolysis of the alkene39 followed
by further oxidation with Jones reagent.37 Global deprotection under Birch reduction conditions40 produced the fully deprotected α-1,2-linked di-mannose.
In addition, β-1-O-allylated galactose was prepared from β-penta-O-acetylated
galactose using allyl alcohol and BF3.OEt2. Eight equivalents of NaIO4 utilized under ruthenium-catalyzed Sharpless conditions41, 42 produced the desired acid in 91% yield. Subsequent deacetylation under mild conditions using
K2CO3 provided the desired fully deprotected galactoside.
2.4. High-throughput synthesis and characterization of functionalized
nanoparticles
The fabrication of functionalized 50:50 CPTEG:CPH nanoparticles was performed via an anti-solvent nanoencapsulation method using an automated robotic deposition apparatus operated by LabVIEW®.32, 33, 43 Galactose and dimannose residues were conjugated to the surface of nanoparticles by a modified
and optimized two-step amine carboxylic acid coupling reaction.21 Briefly, the
first reaction was performed at 4 °C by incubating the nanoparticle suspension
(100 mg/mL) with 12 equivalents (eq.) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), 12 eq. of N-hydroxysuccinimide (NHS),
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and 10 eq. of ethylenediamine in nanopure water for 9 h with constant agitation using a rotor shaker (Scientific Industries, Bohemia, NY). Nanoparticles
were washed twice by centrifugation (10,000 rpm for 5 min) with the addition
of nanopure water and sonication (at 40 Hz for 30 s). The second reaction was
performed at 4 °C in a nanoparticle suspension (50 mg/mL) in nanopure water with 12 eq. of EDC, 12 eq. of NHS and 10 eq. of the corresponding saccharide (i.e., galactose or di-mannose) or glycolic acid (linker between saccharide
and nanoparticles; a control treatment for AMφ experiments) for 9 h with constant agitation. Nanoparticles were washed once and dried under vacuum for 6 h.
The automated set up was used to accurately dispense solutions of EDC, ethylenediamine, and NHS for the first reaction, and solutions of EDC, NHS, and saccharides in the second reaction to increase the throughput of the process. Particle morphology was characterized by scanning electron microscopy (SEM, FEI
Quanta 250, Kyoto, Japan), and hydrodynamic size and ζ-potential were determined by dynamic light scattering (DLS, Zetasizer Nano, Malvern Instruments
Ltd., Worchester, UK). The saccharide concentration conjugated to the nanoparticles was measured using a high throughput phenol sulfuric acid assay as previously described.21, 44
2.5. Mice
Wild type (WT) C57BL/6 (B6) mice were purchased from Harlan Laboratories
(Indianapolis, IN) and macrophage mannose receptor deficient (MMR−/−) B6
mice were a generous gift from Dr. Mary Ann McDowell of the University of
Notre Dame. Mice were housed in specific pathogen-free conditions where all
bedding, caging, and feed were sterilized prior to use. All animal procedures
were conducted with the approval of the Iowa State University Institutional
Animal Care and Use Committee.
2.6. Cell harvesting and culture
Murine alveolar macrophages (AMφ) from WT and MMR−/− B6 mice were harvested by bronchoalveolar lavage as previously described.6, 7, 45 Briefly, mice
were euthanized and a sterile catheter inserted into the trachea of each mouse.
Using a 1 mL syringe fitted with the catheter, 0.75 mL of room temperature,
sterile PBS was gently infused into the lungs and then aspirated back into syringe. This process was repeated six times while externally massaging the chest.
Following collection, lavage fluid was immediately placed on ice prior to centrifugation (250× g, 10 min, 4 °C). Cell viability was then assessed using trypan blue. Cells were cultured in Complete Tissue Culture Medium (CTCM) containing Dulbecco’s Modified Eagle Medium with 4.5 mg of glucose/mL, 2 mm
l-glutamine, 100 U penicillin, 100 μg streptomycin/mL, 25 mm HEPES and
10% fetal bovine serum in six-well plates at a density of 5 × 105 cells/well for
8 h at 37 °C and 5% CO2. After 6 h of incubation, non-adherent cells were discarded and adherent cells (>90%) were incubated overnight prior to treatment.
Non-functionalized or functionalized nanoparticles were incubated with AMφ
at a concentration of 0.125 mg/mL. Non-stimulated AMφ and AMφ stimulated
with Escherichia coli O111:B4 lipopolysaccharide (LPS, 200 ng/mL Sigma–Aldrich, St. Louis, MO) were used as negative and positive controls, respectively.
After 48 h, supernatants were collected for quantification of cytokines and nitrites. Cells were stained for flow cytometric analysis. Bone marrow-derived
macrophages (BMMφ) were derived as previously described.46, 47 Briefly, cells
were obtained from WT and MMR−/− B6 mouse bone marrow and plated in a
150 × 15 mm Petri dish with 30 mL CTCM supplemented with 30% L-cell conditioned medium. After 2 days, an additional 20 mL of CTCM with 30% L-cell
conditioned medium was added to the cultures. At day 6, adherent cell populations were harvested by placing the plates on ice for 20 min and then scraping with a cell scraper. After washing in PBS, live cells were counted and resuspended in CTCM prior to treatment with nanoparticles and stimulants as
described for the AMφ.
2.7. Cell surface marker evaluation
Flow cytometric evaluation of cell surface markers was performed by modifying a previously described protocol.48 Briefly, cells were washed in 2 mL
of fluorescence-activated cell sorting buffer (FACS buffer, 0.1% sodium azide
and 0.1% bovine serum albumin in phosphate buffer saline). Fcγ receptors
were blocked with PBS containing 100 μg/mL rat anti-mouse CD16/CD32 antibody (BD Bioscience, San Diego, CA) and 1 mg/mL rat IgG for 30 min at
4 °C to prevent non-specific binding. AMφ were incubated with appropriate
antibodies or isotype controls for 15 min on ice. Antibodies used for assessment of activation included phycoerythrin (PE)-Cy7 conjugated anti-mouse
F4/80 (clone BM8), fluorescein isothiocyanate (FITC)-conjugated anti-mouse/
rat MHC II (I-A/I-E, clone M5/114.15.2), allophycocyanin (APC) anti-mouse
CD40 (clone 1C10) and PE conjugated anti-mouse MHC I (H-2Kb, clone
AF6-88.5.5.3). These antibodies and their respective isotype controls were
purchased from eBioscience (San Diego, CA). APC-Cy7 anti-mouse CD86
(clone GL-1) was purchased from Biolegend (San Diego, CA). Antibodies
used to evaluate CLR expression included F4/80, biotin conjugated anti-mouse
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CD209 (clone 5H10) and PE-Texas red conjugated streptavidin purchased
from BD Biosciences, FITC anti-mouse CD206 (MMR, clone MR5D3) purchased from Biolegend and PE-CD301a/b (MGL1/2, affinity purified PAb catalog # FAB4297P) purchased from R&D systems (Minneapolis, MN). Samples were acquired using a FACSAria III flow cytometer (BD Biosciences) and
the data were analyzed using FlowJo software (TreeStar Inc., Ashland, OR).
2.8. Nanoparticle internalization
At the time of fabrication, nanoparticles were loaded with cadmium selenide
quantum dots (QDs; emission at 630 nm) prior to functionalization. The QDs
were kindly provided by Dr. Aaron Clapp of Iowa State University. QD-loaded
functionalized and non-functionalized nanoparticles were used to stimulate
AMφ for 48 h. Cells were then analyzed by flow cytometry to identify the
populations of AMφ that had phagocytosed nanoparticles (i.e., nanoparticlepositive versus nanoparticle-negative) as described previously.49 A QD control (background) was used to account for “false positives” because of QDs
released due to nanoparticle degradation. QD-loaded, functionalized (e.g., dimannose) and non-functionalized nanoparticles were incubated in cell culture
medium for 48 h. After centrifugation (250× g, 10 min, 4 °C), supernatants
were added to AMφ. After 48 h, the fluorescence registered for these control
groups was considered as background. Cells were labeled with the above-described F4/80, MHC II, CD40, CD86 and CD301a/b antibodies as wells as
with Pacific blue anti-mouse MHC I (H-2Kb, clone AF6-88.5) purchased from
Biolegend, biotin anti-mouse CD209 and PerCP-Cy5.5 conjugated streptavidin purchased from eBioscience.
2.9. Cytokine and reactive nitrogen species assays
After stimulation for 48 h with non-functionalized or functionalized nanoparticles, cell-free supernatants were assayed for IL-1β, IL-10, TNF-α, IL-6, and
IL-12p40 using a multiplex cytokine assay in conjunction with a Bio-Plex 200
System (Bio-Rad, Hercules, CA) as described elsewhere.33 Griess Reagent
(Invitrogen, Carlsbad, CA) was used according to the manufacturer’s specifications to determine nitrite concentration as an indirect method to measure
production of reactive nitrogen species.
2.10. Statistical analysis
The statistical software JMP®7 was used to analyze all data. Tukey’s HSD
was used to determine significant differences among treatments. A student’s T
test was employed to determine the significant differences between AMφ harvested from WT versus MMR−/− mice and between nanoparticle positive and
negative AMφ. All p values < 0.05 were considered significant.

3. Results
3.1. Synthesis and characterization of functionalized polyanhydride nanoparticles
Amphiphilic 50:50 CPTEG:CPH copolymer was synthesized as described previously.31 The molecular weight (Mw) of the copolymer
was 8000 Da and 1H NMR spectra of the copolymer were consistent with previously published data.31, 33, 35 Particle morphology was
evaluated by SEM and was found to be consistent with previously
published results (c.f. References [21], [33], & [43]; and data not
shown). The average diameter of the non-functionalized nanoparticles was 163 ± 24 nm with a ζ-potential of −23 ± 2.5 mV (consistent with the presence of carboxylic acids on the surface). The glycolic acid (linker only) functionalized nanoparticles had an average
diameter of 261 ± 44 nm and a ζ-potential of 20 ± 2.7 mV, while
di-mannose functionalized and galactose functionalized nanoparticles had average diameters of 271 ± 40 nm and 263 ± 44 nm, respectively, with ζ-potentials of 26 ± 1.9 mV. The positive charges of the
functionalized particles were consistent with previously published
data21 and are attributed to the presence of free ethylenediamine
groups on the surface of the particles. Measuring the ζ-potential of
ethylenediamine-functionalized nanoparticles (determined to be
31 ± 3.6 mV) further corroborated this result. These data indicate
that partial capping of the ethylenediamine groups occurs when the
saccharide is conjugated in the second reaction of the functionalization process. The di-mannose and galactose concentrations attached

C h av e z -S a n t o s c o y

et al. in

B i o m at e r i a l s 33 (2012)

to the nanoparticles were normalized to the total mass of nanoparticles. The di-mannose concentration was 13.2 ± 3.5 μg/mg, consistent
with previous work.21 The galactose concentration conjugated to the
nanoparticles was 15.2 ± 4.7 μg/mg.
3.2. Influence of functionalized polyanhydride nanoparticles on
AMφ activation
Previous work from our laboratories has highlighted the intrinsic
adjuvant activity of polyanhydride micro and nanoparticles, as evidenced by their ability to activate DCs.48, 49 In the current study,
we observe, for the first time, increased expression of surface markers associated with antigen processing and presentation (MHC I and
II) and T cell co-stimulation (CD86 and CD40) in primary AMφ
cultured with non-functionalized (NF) polyanhydride nanoparticles as compared to non-stimulated AMφ (Figure 1A–D). Culturing AMφ with non-functionalized polyanhydride nanoparticles also
enhanced surface expression of CLRs (MMR, MGL and CIRE) in
comparison to non-stimulated AMφ and AMφ stimulated with LPS
(Figure 1E–G).
Functionalization of polyanhydride nanoparticles with either dimannose or galactose provided a significant enhancement in the expression of MHC I and CD40 on the surface of AMφ in comparison to treatment with either non-functionalized particles or particles
functionalized with only glycolic acid, the linker used to attach the
carbohydrates to the nanoparticles (Figure 1A and D). AMφ MHC
II and CD86 expression was significantly increased over non-functionalized particles regardless of the nanoparticle functionalization
(Figure 1B and C), with the greatest enhancement in MHC II observed on AMφ co-cultured with di-mannose functionalized particles (Figure 1B). As compared to non-functionalized nanoparticles,
expression of the MMR on AMφ was only significantly enhanced
upon incubation with di-mannose functionalized nanoparticles (Figure 1E). Similarly, co-culture with galactose functionalized nanoparticles significantly increased AMφ MGL expression (Figure 1F). No
significant enhancement in CIRE expression was observed when
AMφ were incubated with functionalized versus non-functionalized
nanoparticles (Figure 1G).
Together, these observations indicate that carbohydrate functionalization of polyanhydride nanoparticles enhanced AMφ activation as compared to non-functionalized particles. In some instances
(e.g., MHC II and CD86 expression), functionalization with only the
glycolic acid linker was sufficient to activate AMφ, indicating that
nanoparticle surface charge contributes to AMφ activation. Finally,
AMφ co-cultured with di-mannose or galactose functionalized particles exhibited enhanced cellular activation profiles that were comparable or superior to those observed in AMφ stimulated with LPS.
3.3. Relationship between functionalized polyanhydride nanoparticle internalization and CD40 expression on AMφ
Phagocytosis of pathogenic bacteria is an important step associated with innate immune mechanisms and results in activated macrophages.50, 51 We, therefore, evaluated the relationship between
nanoparticle internalization and AMφ activation.49 Internalization of,
and not just association with, nanoparticles by AMφ was confirmed
by confocal microscopy (data not shown). Two populations of cells
were identified—cells that internalized nanoparticles (QD-loaded
nanoparticle-positive) and cells that did not internalize particles
(nanoparticle-negative). Internalization of nanoparticles, regardless
of functionalization status, was found to be required for the enhanced
expression of CD40 on AMφ (Figure 2B), but not for the expression
of CD86 (Figure 2A), MHC I, or MHC II (data not shown).
Interestingly, the nanoparticle-positive cells that internalized dimannose but not galactose-functionalized nanoparticles expressed
significantly greater levels of the MMR as compared to nanoparticle-negative cells (Figure 2C). A similar relationship was observed
for galactose but not di-mannose functionalized particles and MGL
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Figure 1. Functionalization of polyanhydride nanoparticles enhanced AMφ expression of MHC, T cell co-stimulatory molecules, and CLRs. After stimulation
with non-functionalized (NF) or functionalized nanoparticles for 48 h, AMφ were harvested and analyzed by flow cytometry for surface expression of (A) MHC
I, (B) MHC II, (C) CD86, (D) CD40, (E) MMR, (F) MGL, or (G) CIRE. LPS stimulated and non-stimulated cells (NS) were used as positive and negative controls, respectively. Data are expressed as the mean ± the SEM of three independent experiments performed in triplicate. Treatments with different letters are significantly different from one another at p < 0.05. MFI = mean fluorescence intensity.
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Figure 2. Internalization of functionalized polyanhydride nanoparticles was required for upregulation of CD40 expression on AMφ. Percent of AMφ that did not
internalize (nanoparticle-negative; □) or did internalize (nanoparticle-positive; ■) nanoparticles after 48 h that were also positive for (A) CD86, (B) CD40, (C)
MMR, (D) MGL, or (E) CIRE. Data are expressed as the mean ± the SEM of three independent experiments performed in triplicate. * Represents a statistically
significant difference between nanoparticle-positive and nanoparticle-negative populations within a treatment at p < 0.05.

expression (Figure 2D). A significant increase in CIRE was observed on AMφ that internalized either non-functionalized or dimannose functionalized nanoparticles but not nanoparticles that
were functionalized with galactose or only the glycolic acid linker
(Figure 2E). Together, these data support an association between internalization of nanoparticles functionalized with specific carbohydrates and the enhanced expression of the cognate receptor specific
for that carbohydrate.

3.4. Influence of functionalized polyanhydride nanoparticles on
AMφ pro-inflammatory cytokine secretion
Previous reports from our laboratory have described the ability of
non-functionalized polyanhydride nanoparticles to enhance secretion of pro-inflammatory cytokines from APCs.32, 48 In this present
work, we sought to extend our findings by asking if functionalization
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Figure 3. Carbohydrate functionalization of nanoparticles differentially influenced pro-inflammatory cytokine secretion. After stimulation with non-functionalized (NF) or functionalized nanoparticles for 48 h, culture supernatants were harvested and assayed for (A) IL-1β, (B) TNF-α, (C) IL-6, or (D) IL-12p40. LPS
stimulated and non-stimulated cells (NS) were used as positive and negative controls, respectively. Mean cytokine production for AMφ stimulated with LPS:
IL-1β = 1021.7 ± 66.5 pg/mL, IL-6 = 7804.3 ± 101.2 pg/mL, TNF-α = 5711.5 ± 181.7 pg/mL, and IL-12p40 = 3637.8 ± 111.6 pg/mL. (E) Nitrate concentration was measured in culture supernatants via a Griess assay as an indirect method to quantify production of reactive nitrogen species. Data are expressed as
the mean ± the SEM of three independent experiments performed in triplicate. Treatments with different letters are significantly different from one another at
p < 0.05.

with specific carbohydrates provides additional stimulatory capacity
to the polyanhydride nanoparticles. Indeed, di-mannose functionalized nanoparticles significantly elevated AMφ production of IL-1β as
compared to all nanoparticle treatments (Figure 3A). Functionalization with either di-mannose or the glycolic acid linker but not galactose enhanced AMφ secretion of TNF-α (Figure 3B). Di-mannose

modification of the nanoparticles provided no additional benefit in
terms of increasing IL-6 or IL-12p40 production (Figure 3C and D).
Of note, functionalization with either the glycolic acid linker alone or
galactose diminished the secretion of IL-12p40 observed when AMφ
were co-cultured with non-functionalized nanoparticles (Figure 3D).
No IL-10 was detected in the culture supernatants of any AMφ co-
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cultured with nanoparticles (data not shown). As shown in Figure 3E,
the di-mannose functionalize particles induced significantly more reactive nitrogen species when compared to the non-stimulated group
(negative control). All the other nanoparticle groups induced levels
of reactive nitrogen species that were similar when compared to the
non-stimulated group (negative control).
3.5. Di-mannose functionalized nanoparticles and engagement of
the MMR
The data depicted in Figure 2 demonstrated that nanoparticle internalization was required for increased CD40 and CLR expression.
Furthermore, we demonstrated that AMφ activation by functionalized nanoparticles was also a consequence of nanoparticle internalization (Figs. 1and 3). Using flow cytometry, we found that any
functionalization of the nanoparticles enhanced uptake by AMφ as
compared to non-functionalized particles (Figure 4, open bars).
To evaluate the role of the MMR on the uptake of di-mannose
functionalized nanoparticles, we isolated AMφ from MMR-deficient
(MMR−/−) mice and co-cultured them with functionalized nanoparticles. As compared to wild type (WT) AMφ, a significant decrease
in the number of internalized nanoparticles was only observed when
di-mannose functionalized nanoparticles were co-cultured with
MMR−/− AMφ (Figure 4, open versus closed bars). These data indicate that di-mannose functionalization of nanoparticles confers a specific interaction of the nanoparticles with the MMR that contributes
to their enhanced internalization. In contrast, nanoparticles functionalized with galactose or only the glycolic acid linker are internalized
via other, non-MMR-dependent pathways. Similar results were obtained using bone marrow-derived macrophages (BMMφ; Supplemental Figure 1).

Figure 4. Di-mannose functionalized nanoparticles enhanced internalization by engaging the macrophage mannose receptor on AMφ. Percent of wild
type (□) and MMR-deficient (MMR−/−;■) AMφ that internalized nanoparticles after 48 h. Data are expressed as the mean ± the SEM of three independent experiments performed in triplicate. * represents a statistically significant difference between wild type and MMR−/− AMφ within a treatment at
p < 0.05. # represents a statistically significant difference from the non-functionalized nanoparticle treatment group for wild type AMφ. ^ represents a statistically significant difference from the non-functionalized nanoparticle treatment group for MMR−/− AMφ.
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Consistent with the internalization data, co-culture of WT AMφ
with di-mannose functionalized nanoparticles significantly increased
the expression of MHC I, MHC II, CD86 and CD40 in comparison to
that observed for MMR−/− AMφ (Figure 5A–D). Similarly, MMR−/−
AMφ secreted significantly less IL-1β and IL-6 as compared to WT
AMφ when co-cultured with di-mannose functionalized nanoparticles (Figure 6A and C). As compared to WT AMφ, reduced levels
of CIRE expression (Figure 5E) and TNF-α and IL-12p40 secretion
(Figure 6B and D) were also observed in MMR−/− AMφ co-cultured
with di-mannose functionalized as well as with non-functionalized
nanoparticles. In contrast, WT and MMR−/− AMφ produced similar
amounts of all cytokines measured following stimulation with LPS,
indicating that MMR−/− AMφ were functionally capable of cytokine
production (data not shown). Likewise, the absence of the MMR had
no negative effect on the increased surface marker expression or cytokine production observed when AMφ were co-cultured with galactose functionalized nanoparticles (Figures 5 & 6), indicating that galactose functionalized particles do not require the MMR to promote
AMφ activation. To rule out that our observations were unique to
AMφ, these analyses were performed using BMMφ and similar results were obtained (Supplemental Figures 2 & 3). Together, these
data support the concept that di-mannose functionalized nanoparticles enhance AMφ activation by engaging the MMR.
4. Discussion
In the present work, we have designed an approach to targeted antigen delivery by functionalizing the surface of polyanhydride
nanoparticles with specific carbohydrates to enable the nanoparticles
to engage C-type lectin receptors on AMφ. Our rationale is that receptor-mediated engagement of nanoparticles will enhance their uptake and the activation of AMφ, leading to the induction of robust
immune responses in the respiratory tract.
Co-culture of functionalized nanoparticles with AMφ significantly increased cell surface expression of MHC I and II, CD86,
CD40 and the C-type lectin receptor CIRE over non-functionalized
nanoparticles (Figure 1A–D and G). Di-mannose and galactose functionalization also enhanced the expression of the MMR and MGL,
respectively (Figure 1E and F). Carbohydrate modification also significantly increased uptake of the nanoparticles by AMφ. Moreover,
the enhanced expression of CD40 on AMφ incubated with functionalized nanoparticles was found to be dependent upon nanoparticle
internalization (Figure 2). The presence of nanoparticles in the coculture was sufficient for enhancement of certain activation markers
(i.e., CD86, MHC I, and MHC II), while internalization was required
for the expression of CD40. Our results show that the targeting of
the C-type lectin receptors MMR, MGL, and CIRE resulted in a
higher percentage of AMφ that internalize nanoparticles (Figure 4,
open bars). This enhanced internalization may improve antigen delivery to antigen processing compartments52–54 and the enhancement
of the expression of co-stimulatory receptors (i.e., CD86 and CD40)
as shown in Figure 1.
Nanoparticle internalization also played a critical role in the enhanced expression of CLRs (Figure 2C–E). MMR expression was increased on AMφ following co-culture with mannose-functionalized
nanoparticles (Figure 1E), and this enhanced expression required internalization of the nanoparticles (Figure 2C). Similar results were
observed for MGL (Figs. 1F and 2D). The expression of the CIRE
receptor was enhanced by most of the nanoparticle formulations, but
only cells that internalized non-functionalized and di-mannose functionalized nanoparticles showed increased expression of this marker
(Figs. 1G and 2E). Several reports have shown that CLRs undergo
internalization and recycling between the plasma membrane and the
endosomal compartments.55–57 Our results indicate that positive selfregulation of specific CLRs occurs upon ligand recognition, subsequently increasing the expression of these markers.
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Figure 5. Di-mannose functionalized nanoparticles enhanced AMφ expression of MHC, T cell co-stimulatory molecules and CLRs by engaging the macrophage
mannose receptor. After stimulation with non-functionalized (NF) or functionalized nanoparticles for 48 h, wild type (□) and MMR-deficient (MMR−/−;■) AMφ
were harvested and analyzed by flow cytometry for surface expression of (A) MHC I, (B) MHC II, (C) CD86, (D) CD40, (E) MGL, or (F) CIRE. Non-stimulated
(NS) cells were used as negative controls. Data are expressed as the mean ± the SEM of three independent experiments performed in triplicate. * Represents a
statistically significant difference between wild type and MMR−/− AMφ within a treatment at p < 0.05. MFI = mean fluorescence intensity. # Represents a statistically significant difference from the NS cells for wild type AMφ. ^ Represents a statistically significant difference from the NS cells for MMR−/− AMφ.

The production of pro-inflammatory cytokines is essential for the
activation of macrophages to stimulate their anti-microbial properties
and for them to initiate adaptive immune responses.58 Di-mannose
functionalization enhanced the production of IL-12p40, IL-1β and
TNF-α (Figure 3A–D). These results are in agreement with studies

demonstrating that the targeting of MMR resulted in the production
of pro-inflammatory cytokines through the activation of NF-κB.59
Although the production of pro-inflammatory cytokines was enhanced by the di-mannose functionalization, the levels secreted were
modest enough to allay concerns about chronic inflammation in the
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Figure 6. Di-mannose functionalized nanoparticles enhanced AMφ pro-inflammatory cytokine production by engaging the macrophage mannose receptor. After stimulation with non-functionalized (NF) or functionalized nanoparticles for 48 h, culture supernatants from wild type (□) and MMR-deficient (MMR−/−;■)
AMφ were harvested and assayed for (A) IL-1β, (B) TNF-α, (C) IL-6, or (D) IL-12p40. Non-stimulated (NS) cells were used as a negative control. Data are expressed as the mean ± the SEM of three independent experiments performed in triplicate. * Represents a statistically significant difference between wild type and
MMR−/− AMφ within a treatment at p < 0.05. # Represents a statistically significant difference from the NS cells for wild type AMφ. ^ Represents a statistically
significant difference from the NS cells for MMR−/− AMφ.

respiratory tract following intranasal administration. The galactose
functionalized nanoparticles resulted in an enhanced production of
cytokines in comparison with the non-stimulated AMφ, but at lower
levels than the non-functionalized nanoparticles, particularly for IL12p40. The release of pro-inflammatory cytokines when the cells
were treated with galactose-functionalized particles was similar to
that of the non-functionalized nanoparticles. These results are consistent with previous studies suggesting that galactose motifs enhanced
the production of cytokines such as IL-12p40 and TNF-α, but not to
the levels obtained when mannose motifs are used.59, 60
The elevated production of reactive nitrogen species has been related to chronic inflammation and cancers of several organs, including lungs.61 Such a response may be needed to combat an infection;
however it would not be desirable consequence following administration of an intranasal vaccine. As shown in Figure 3E, all the
nanoparticle groups induced levels of reactive nitrogen species that
were similar when compared to the non-stimulated group (negative
control). Collectively, these data demonstrate that di-mannose functionalization significantly enhanced the expression of cell surface
makers and the production of relevant cytokines, leading to an activated phenotype of AMφ that is necessary for the initiation of robust
mucosal immune responses.

To further assess the role of MMR-specific recognition of dimannose functionalized nanoparticles, studies were performed using
AMφ harvested from MMR−/− mice. Statistically significant differences were observed in the internalization of di-mannose functionalized nanoparticles between AMφ harvested from wild type and
MMR−/− mice (Figure 4), indicating that the MMR significantly
contributes to the enhanced uptake observed when polyanhydride
nanoparticles are functionalized with di-mannose. Enhanced uptake was also observed for glycolic acid functionalized nanoparticles as compared to non-functionalized nanoparticles. This may be
attributed to the hydrophilic properties conferred by the mannose
and glycolic acid groups to the surface of the particles that may increase their internalization in comparison to more hydrophobic surfaces (i.e., non-functionalized nanoparticles). This observation is
consistent with previously published data that shows that hydrophilic
chemistries are more readily internalized by AMφ and DCs.49, 62 As
expected, the absence of the MMR did not negatively affect the enhanced uptake of galactose-functionalized nanoparticles. The enhanced AMφ activation phenotype (i.e., above that induced by nonfunctionalized nanoparticles) observed following co-culture with
di-mannose functionalized nanoparticles was also found to be dependent upon the presence of the MMR (Figures 5 & 6). This finding
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suggests that specific engagement of the MMR further enhances the
expression of cell surface markers and cytokine production. As indicated before, mannose is a component of the surface of many respiratory pathogens, including Y. pestis, M. tuberculosis, S. pneumoniae
and influenza viruses, indicating that the MMR may be involved in
how these pathogens are recognized by macrophages and DCs. Typically, upon encountering pathogens, these APCs upregulate expression of antigen presentation and co-stimulatory molecules as well as
secrete cytokines to efficiently prime the naïve T cells that help activate B cells. Our results indicate that di-mannose functionalized
nanoparticles may have pathogen-like characteristics with respect to
their APC activation abilities.
Together, these studies indicate that CLR targeting may be an effective strategy to activate AMφ that, in turn, may be critical to the
implementation of efficacious intranasal vaccines. Functionalized
nanoparticles provide a versatile and robust platform that facilitates
enhanced expression of antigen presentation and co-stimulatory molecules and secretion of the cytokines responsible for initiating and
maintaining adaptive immunity. By innovatively engaging mechanisms or pathways that activate APCs, these studies indicate that it is
feasible to develop an immunization regimen that safely and efficaciously induces protective immunity without the need to induce adverse or deleterious host responses.
5. Conclusions
The approach outlined in this present work demonstrates that rational design of efficacious vaccine adjuvants can be achieved by targeting CLRs on APCs. Specifically, we describe the functionalization
of polyanhydride nanoparticles with two conserved carbohydrate
structures commonly found on the surface of respiratory pathogens,
di-mannose and galactose. The addition of these carbohydrates significantly enhanced the intrinsic adjuvant activity of our polyanhydride nanovaccine platform by further upregulating AMφ surface
expression of MHC I and II, CLRs, the T cell co-stimulatory molecules CD86 and CD40 and the secretion of pro-inflammatory cytokines. Moreover, we demonstrate that the macrophage mannose receptor (MMR) played a central role in the activation of AMφ as well
as the uptake of di-mannose functionalized polyanhydride nanoparticles. These studies provide important insights into the design, modification, and rational selection of intranasal vaccine carriers and/or
adjuvants.
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Appendix A, containing Supplemental Figures 1–3, follows.

Supplementary Information

Supplemental Figure 1. Di-mannose functionalized nanoparticles enhanced internalization
by engaging the macrophage mannose receptor on bone marrow-derived macrophages
(BMMɸ). Percent of wild type () and MMR-deficient (MMR-/-; ) BMMɸ that internalized
nanoparticles after 48 h. Data are expressed as the mean ± the SEM of three independent
experiments performed in triplicate. * represents a statistically significant difference between wild
type and MMR-/- BMMɸ within a treatment at p < 0.05. # represents a statistically significant
1

difference from the non-functionalized nanoparticle treatment group for wild type BMMɸ. ^
represents a statistically significant difference from the non-functionalized nanoparticle treatment
group for MMR-/- AMɸ.

2

3

Supplemental Figure 2. Di-mannose functionalized nanoparticles enhanced bone marrowderived macrophage (BMMɸ) expression of MHC, T cell co-stimulatory molecules and
CLRs by engaging the macrophage mannose receptor. After stimulation with nonfunctionalized (NF) or functionalized nanoparticles for 48 h, wild type () and MMR-deficient
(MMR-/-; ) BMMɸ were harvested and analyzed by flow cytometry for surface expression of (A)
MHC I, (B) MHC II, (C) CD86, (D) CD40, (E) MGL, or (F) CIRE. Non-stimulated (NS) cells were
used as negative controls. Data are expressed as the mean ± the SEM of three independent
experiments performed in triplicate. * represents a statistically significant difference between wild
type and MMR-/- BMMɸ within a treatment at p < 0.05. MFI = mean fluorescence intensity. #
represents a statistically significant difference from the NS cells for wild type AMɸ. ^ represents a
statistically significant difference from the NS cells for MMR-/- AMɸ.

4

Supplemental Figure 3. Di-mannose functionalized nanoparticles enhanced bone marrowderived macrophage (BMMɸ) pro-inflammatory cytokine production by engaging the
macrophage mannose receptor. After stimulation with non-functionalized (NF) or
functionalized nanoparticles for 48 h, culture supernatants from wild type () and MMR-deficient
(MMR-/-; ) BMMɸ were harvested and assayed for (A) IL-1β, (B) TNF-α, (C) IL-6, or (D) IL12p40. Non-stimulated (NS) cells were used as a negative control. Data are expressed as the
mean ± the SEM of three independent experiments performed in triplicate. * represents a
statistically significant difference between wild type and MMR-/- BMMɸ within a treatment at p <
5

0.05. # represents a statistically significant difference from the NS cells for wild type AMɸ. ^
represents a statistically significant difference from the NS cells for MMR-/- AMɸ.
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